Fernandez Rivera, ConstantinoCalvo Rodríguez, MaríaPoveda, José LuísPascual, JulioCrespo, MartaGomez, GonzaloCabello Pelegrin, SheilaPaul, JavierLauzurica, RicardoPerez Mir, MònicaMoreso, FrancescPerelló, ManelAndres, AmadoGonzález, EstherFernandez, AnaMendiluce, AliciaFernández Carbajo, BeatrizSanchez Fructuoso, AnaCalvo, NatividadSuarez, AlejandroBernal Blanco, GabrielOsuna, AntonioRuiz-Fuentes, M CarmenMelilli, EdoardoMontero Perez, NuriaRamos, AnaFernández, BeatrizLópez, VerónicaHernandez, DomingoBetter study2024-02-192024-02-192021-12-17http://hdl.handle.net/10668/19932http://hdl.handle.net/20.500.12105/18521Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P engVoRhttp://creativecommons.org/licenses/by-nc/4.0/bioavailabilityclinical practicepharmacokineticsrenal transplantationtacrolimustreatment failureBiological AvailabilityDrug Administration ScheduleGraft RejectionHumansImmunosuppressive AgentsKidney TransplantationProspective StudiesTacrolimusTransplant RecipientsAttribution-NonCommercial 4.0 International34851532363e1455010.1111/ctr.145501399-0012Clinical transplantationopen access